3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Classical hematology
4
Conditions
Hemophilia A
4
Interventions
Carboplatin
36
Cisplatin
32
pembrolizumab
30
Paclitaxel
29
Pemetrexed
22
Gemcitabine
21
Nivolumab
19
Dexamethasone
17
Rituximab
16
Fluorouracil
13
Docetaxel
13
durvalumab
12
Ipilimumab
12
Capecitabine
12
Cyclophosphamide
11
atezolizumab
10
130-nm albumin-bound paclitaxel
10
olaparib
9
Trastuzumab
9
Lenalidomide
9
Doxorubicin
9
Cytarabine
9
Bevacizumab
9
daratumumab
8
Oxaliplatin
8
Bortezomib
8
Vinorelbine
7
Prednisone
7
Leucovorin
7
venetoclax
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Has announcements
×
emicizumab
×
Clear all
NCT03020160
2023-01-11
HAVEN 4
Hoffmann-La Roche
Phase 3
Completed
48 enrolled
44 charts
1 FDA
NCT02847637
2022-11-16
HAVEN 3
Hoffmann-La Roche
Phase 3
Completed
152 enrolled
46 charts
1 FDA
NCT02622321
2021-06-24
HAVEN 1
Hoffmann-La Roche
Phase 3
Completed
113 enrolled
45 charts
1 FDA
NCT02795767
2021-06-02
HAVEN 2
Hoffmann-La Roche
Phase 3
Completed
88 enrolled
65 charts
1 FDA